



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Tong-Xia Xia,
✉ xtx0925@163.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 30 October 2025
ACCEPTED 31 October 2025
PUBLISHED 13 November 2025

CITATION
Zhu Y, He C, Cao S-C, Li H-J, Cai R-X, Bai Z-J and Xia T-X (2025) Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma.
Front. Pharmacol. 16:1735585.
doi: 10.3389/fphar.2025.1735585

COPYRIGHT
© 2025 Zhu, He, Cao, Li, Cai, Bai and Xia. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

Yan Zhu^{1†}, Cheng He^{1†}, Shi-Chao Cao¹, Hui-Jun Li², Ru-Xue Cai³, Zhao-Jun Bai⁴ and Tong-Xia Xia^{1,5*}

¹Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China, ²Department of Pharmacy, Zunyi Bozhou District People's Hospital, Zunyi, Guizhou, China, ³Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Economic and Technological Development District, Guiyang, Guizhou, China, ⁴Guangxi Shenli Pharmaceutical Co., Ltd., Yulin, Guangxi, China, ⁵School of Nursing, Zunyi Medical University, Zunyi, Guizhou, China

KEYWORDS

cost-effectiveness analysis, advanced hepatocellular carcinoma, cabozantinib, atezolizumab, sorafenib

A Correction on

Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

by Zhu Y, He C, Cao S-C, Li H-J, Cai R-X, Bai Z-J and Xia T-X (2025). *Front. Pharmacol.* 16: 1556304. doi: 10.3389/fphar.2025.1556304

Affiliation 1 Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China was omitted for author Tong-Xia Xia. This affiliation has now been added for author Tong-Xia Xia.

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.